HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials.

This article has no abstract
Epistemonikos ID: a00b298449c5ab98dc74525398a0960d637baa34
First added on: Feb 10, 2025